Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer by Nyrop, K.A. et al.
Patient-Reported Symptom Severity, Interference With Daily 
Activities, and Adverse Events in Older and Younger Women 
Receiving Chemotherapy for Early Breast Cancer
Kirsten A. Nyrop, PhD 1,2; Allison M. Deal, MS2; Yi Tang Chen, BA3; Bryce B. Reeve, PhD 4; Ethan M. Basch, MD 1,2; 
William A. Wood, MD1,2; Shlomit S. Shachar, MD5; Lisa A. Carey, MD1,2; Katherine E. Reeder-Hayes, MD 1,2; 
E. Claire Dees, MD1,2; Trevor A. Jolly, MBBS1,2; Gretchen G. Kimmick, MD, MS4; Meghan S. Karuturi, MD 6; Raquel E. 
Reinbolt, MD 7; JoEllen C. Speca, MD1; Jordan T. Lee, MA 8; Addison Brenizer, BA2; and Hyman B. Muss, MD1,2
BACKGROUND: To the authors’ knowledge, it is unknown whether patient-reported symptom severity and symptom interference with 
daily activities differ between younger (aged <65 years) and older (aged ≥65 years) women receiving similar chemotherapy regimens
for early breast cancer (EBC). METHODS: Study participants rated 17 side effects of chemotherapy regimens currently in use in clinical 
practice (2014-2019). RESULTS: Of 284 women with EBC (stage I-III), approximately 57% were aged <65 years and 43% were aged ≥65
years. For anthracycline-based regimens, a higher percentage of younger women reported moderate, severe, or very severe (MSVS) 
hot flashes (49% vs 18%) (P < .001). For nonanthracycline regimens, a higher percentage of younger women reported MSVS hot flashes
(38% vs 19%) (P = .009) and a lower percentage reported MSVS arthralgia (28% vs 49%) (P = .005). With regard to symptom interfer-
ence with daily activities, a higher percentage of younger women being treated with anthracycline-based regimens reported MSVS hot 
flashes (32% vs 7%) (P = .001) and myalgia (38% vs 18%) (P = .02). For nonanthracycline chemotherapy, a higher percentage of younger
women reported MSVS interference for hot flashes (26% vs 9%) (P = .006) and lower percentages reported abdominal pain (13% vs 28%) 
(P = .02). Overall, there were no significant differences noted among younger versus older patients with regard to hospitalizations (19%
vs 12%; P = .19), dose reductions (34% vs 31%; P = .50), dose delays (22% vs 25%; P = .59), or early treatment discontinuation (16% vs 16%; 
P = .9546). CONCLUSIONS: Older and younger women with EBC who were treated with identical chemotherapy regimens generally expe-
rienced similar levels of symptom severity, symptom-related interference with daily activities, and adverse events. Cancer 2021;127:957-967.  
© 2020 American Cancer Society. 
LAY SUMMARY: 
• In the current study, women receiving chemotherapy for early breast cancer rated the severity of 17 symptoms and symptom interfer-
ence with their activities of daily living.
• Older (aged ≥65 years) and younger (aged <65 years) women who received identical chemotherapy regimens generally experienced
similar levels of symptom severity, symptom-related interference with daily activities, and adverse events.
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INTRODUCTION
Breast cancer is largely a disease of aging, with the incidence of new cases rising with age.1 Early detection and improved 
adjuvant therapies have resulted in steady improvements in survival rates,1 with newer chemotherapies and radiother-
apy being important components of these treatment advances. Women with early breast cancer who are aged ≥65 years 
remain underrepresented in treatment trials.2,3 However, clinician-graded toxicity scores (the National Cancer Institute’s 
Common Terminology Criteria for Adverse Events [CTCAE])4,5 obtained from treatment trials have shown that older 
women can both tolerate and benefit from newer treatments.6-8 These findings suggest that age alone should not be the 
sole criterion for decisions regarding chemotherapy. Instead, treatment options should be based on an assessment of the 
patient’s physical reserves as well as the patient’s goals, life expectancy, and tumor biology.9-11
Patient-reported symptom monitoring during treatment has emerged as an important complement to cli-
nician-assessed toxicity, both in clinical trials12,13 as well as in clinical practice.14-16 We previously observed that 
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patient-reported symptom severity varies significantly 
among 4 chemotherapy regimens commonly used in 
current clinical practice for the treatment of early breast 
cancer, and that patients receiving anthracycline-based 
regimens had significantly higher rates of moderate, se-
vere, or very severe (MSVS) symptoms compared with 
patients receiving regimens that were not anthracycline 
based.17 In this sample of patients, we also observed 
that clinicians often underestimate the severity of che-
motherapy side effects compared with patient reports of 
symptom severity.18
Clinician concerns regarding an increased risk 
of toxicity in older patients who are receiving adju-
vant chemotherapy can result in undertreatment and 
may, in part, explain the poorer breast cancer–specific 
survival noted in older women with early-stage breast 
cancer.19 In the current study, we investigated whether 
patient-reported symptom severity differs between 
younger women (those aged <65 years) and older 
women (those aged ≥65 years) receiving similar chemo-
therapy regimens. We chose age 65 years because this 
is the cut point commonly used to define the “older” 
patient, most likely relating to the age for receiving 
Medicare. We also investigated symptom “interference 
with activities of daily living,” which to our knowl-
edge is a seldom-reported side effect. The current study 
data included 17 symptoms monitored prospectively 
throughout chemotherapy. We also compared hospital-
izations and treatment changes (dose reduction, early 
treatment discontinuation). The objective of the cur-
rent study was to further our understanding of chemo-
therapy treatment tolerability in older compared with 
younger women with early breast cancer.
MATERIALS AND METHODS
Study Participants
The current study was an ancillary analysis of data from 
3 studies investigating self-directed walking during 
chemotherapy for early breast cancer. The studies were 
approved by the University of North Carolina at Chapel 
Hill (UNC) Lineberger Comprehensive Cancer Center 
protocol review committee and the UNC institutional 
review board. The trial is registered at ClinicalTrials.gov 
(ClinicalTrials.gov identifier NCT02328313) and is a 
multisite study with institutional review board approval 
at participating sites (UNC, Duke University Medical 
Center, The University of Texas MD Anderson Cancer 
Center, and the Ohio State University Comprehensive 
Cancer Center). The enrollment period was from March 
2014 to December 2019. The protocols were identical 
with the exception of varying age criteria: women aged 
21 to 64 years at the time of breast cancer diagnosis 
(ClinicalTrials.gov identifier NCT02167932), women 
aged ≥65 years at the time of breast cancer diagnosis 
(ClinicalTrials.gov identifier NCT02328313), and 
women aged ≥21 at the time of breast cancer diagnosis 
(ClinicalTrials.gov identifier NCT03761706). For all 
3 studies, women with histologically confirmed state 
I to stage III breast cancer20 who were scheduled to re-
ceive (neo)adjuvant chemotherapy were approached in 
the clinic, confirmed for eligibility (clinician consent to 
engage in moderate walking), and invited to participate 
by providing written informed consent meeting all fed-
eral, state, and institutional guidelines. Further details 
regarding the patient population have been published 
previously.17,18,21
Chemotherapy Regimens
Chemotherapy regimens were administered at the dis-
cretion of the treating oncologist in consultation with 
the patient, depending on the breast cancer stage22 and 
phenotype. For the current study, there was no a priori 
selection of patients receiving specific chemotherapy 
regimens. Four regimens accounted for approximately 
81% of all regimens in the primary studies: 1) dose-
dense doxorubicin and cyclophosphamide followed by 
paclitaxel (AC-T) (30% of patients); 2) docetaxel and 
cyclophosphamide (TC) (27% of patients); 3) doc-
etaxel and carboplatin with anti-HER2 therapy (TCH) 
(16% of patients); and 4) doxorubicin and cyclophos-




At infusion visits throughout chemotherapy, patients 
rated 17 symptoms using a patient-reported symptom 
monitoring form: fatigue, insomnia, anxiety, depression, 
dyspnea, peripheral neuropathy, joint pain and/or arthral-
gia, muscle pain and/or myalgia, abdominal pain, general 
pain, edema of the extremities, constipation, diarrhea, 
nausea, vomiting, mucositis, and hot flashes. For patients 
with infusion schedules every 2 or 3 weeks, symptom re-
ports were collected at the time of each visit; for patients 
with weekly infusion schedules, symptom reports were 
collected every 2 weeks. The day of infusion was used 
for data collection to standardize the time frame (“past 
7 days”) across all 17 symptoms and all regimens and to 
reduce the burden on study participants.
For 2 studies (ClinicalTrials.gov identifiers 
NCT02167932 and NCT02328313), symptoms were 
collected using a patient-tested measure called Patient-
Reported Symptom Monitoring (PRSM).13 The PRSM 
studies predated the widespread availability of the Patient-
Reported Outcomes–CTCAE (PRO-CTCAE),23,24 
which was used in the third study (ClinicalTrials.gov 
identifier NCT03761706) when it became available to 
the general community. The phrasing to elicit symp-
tom severity (intensity and/or frequency) and symptom 
interference with daily activities (“keep you from doing 
things you usually do”) over the past 7 days was similar 
between the PRSM and PRO-CTCAE (see Supporting 
Information A for PRSM and Supporting Information B 
for PRO-CTCAE). Response options were on a 5-point 
Likert-type scale from 1 (least) to 5 (worst). The max-
imum rating of 1, 2, 3, 4, or 5 was recorded for each 
symptom per patient. This approach to side effects assess-
ment is analogous to CTCAE reporting in clinical trials, 
in which the maximum toxicity grade at any time during 
chemotherapy is reported. Our specific interest was the 
percentage of patients who rated individual symptoms as 
“moderate,” “severe,” or “very severe” (MSVS) at any time 
during chemotherapy.
Demonraphics, breast caincer dianinosis, 
treatmeint, aind adverse eveints
Age, race, educational level, marital status, living ar-
rangements, and employment status were reported by 
study participants using a pretreatment questionnaire. 
Research staff reviewed the electronic medical record 
(EPIC Systems, Verona, Wisconsin) for data pertaining 
to breast cancer diagnosis and treatment and body mass 
index. Staff also collected data from the electronic medi-
cal record regarding chemotherapy-related adverse events 
such as hospitalizations, dose delays, dose reductions, and 
treatment discontinuations. Any hospitalizations outside 
Epic@UNC (including outside Care Everywhere) were 
not captured.
Statistical Analysis
Descriptive statistics are reported for all measures. Chi-
square tests, Fisher exact tests, and Student t tests were 
used to compare differences in patient characteristics, 
breast cancer diagnosis and treatment, patient-reported 
chemotherapy toxicities, and chemotherapy adverse 
events between older and younger patients. Statistical sig-
nificance was set at P = .05. All analyses were conducted 




Table 1 provides an overview of patient characteristics, 
comparing 163 patients aged <65 years with 121 patients 
aged ≥65 years. With regard to chemotherapy use, a 
higher percentage of younger patients received neoadju-
vant chemotherapy (P = .007) and an anthracycline-based 
regimen (P = .021). Specific chemotherapy regimens 
varied by age between younger versus older patients 
(P < .001): AC-T: 36% versus 25%; AC-TC: 11% versus 
3%; TC: 25% versus 28%; TCH: 20% versus 12%; and 
other: 10% versus 31%. There were no significant differ-
ences with regard to the mean number of symptom re-
ports collected from younger versus older patients noted 
by regimen: AC-T: 8 reports versus 9 reports (P = .92); 
AC-TC: 13 reports versus 13 reports (P = .67); TC: 4 
reports versus 4 reports (P = .17); and TCH: 6 reports 
versus 6 reports (P = .52).
Symptom “Severity”
To account for the type of chemotherapy regimen ad-
ministered, we separately analyzed anthracycline-based 
and non–anthracycline-based regimens for the percent-
age of symptoms rated as MSVS by younger versus 
older patients (Table 2). Among patients receiving an-
thracycline-based regimens (Fig. 1), a higher percentage 
of younger women reported MSVS hot flashes (49% 
vs 18%) (P < .001). Among women not receiving an-
thracycline-based regimens (Fig. 2), a higher percentage 
of younger women reported MSVS hot flashes (38% 
vs 19%) (P = .009) and a lower percentage reported 
MSVS arthralgia (28% vs 49%) (P = .005). For all 
other symptoms, there were no significant differences 
in symptom severity scores observed between the age 
groups.
In Supporting Table 1, symptom severity in 
younger versus older patients is compared for the 4 
most common chemotherapy regimens: AC-T, AC-TC, 
TC, and TCH. Again, there were minimal differences 
in symptom severity noted between the 2 age groups. A 
higher percentage of younger women reported MSVS 
hot flashes during treatment with AC-T (50% vs 23%; 
P = .01) and TCH (39% vs 7%; P = .04), and a higher 
percentage reported MSVS constipation during treat-
ment with AC-TC (78% vs 0%; P < .01). During 
treatment with TC, higher percentages of older women 
reported MSVS arthralgia (25% vs 50%; P = .03), my-
algia (23% vs 47%; P = .03), and nausea (8% vs 29%; 
P = .02).
Symptom Interference With Daily Activities
Figures 1 and 2 illustrate the percentage of patients reporting 
MSVS symptom interference with activities of daily 
living. Overall, both younger and older patients reported 
that symptom interference was lower than symptom 
severity. Among patients receiving anthracycline-based 
chemotherapy regimens (Fig. 1) (Table 3), a higher 
percentage of younger women reported MSVS interference 
associated with hot flashes (32% vs 7%; P = .001) and 
myalgia (38% vs 18%; P = .02). Among women not 
receiving anthracycline-based regimens (Fig. 2) (Table 3), 
a higher percentage of younger women reported MSVS 
TABLE 1. Patient Characteristics
Variable Overall N = 284 Age <65 Years N = 163 Aged ≥65 Years N = 121 Pa
Age, y 57 (SD, 12.9) 48 (SD, 9.2) 70 (SD, 4.4) <.001
Race
White 208 (73%) 112 (68%) 96 (79%) .12
Black 61 (22%) 40 (25%) 21 (17%)
Other 15 (5%) 12 (7%) 4 (3%)
Educational level
≤High school 40 (14%) 19 (12%) 21 (18%) .18
>High school 241 (86%) 142 (88%) 99 (83%)
Breast cancer stage20
I 67 (24%) 31 (19%) 36 (30%) .07
II 145 (51%) 85 (52%) 60 (50%)
III 72 (25%) 47 (29%) 25 (21%)
HER2 positive 73 (26%) 43 (26%) 30 (25%) .76
HR positive 90 (60%) 17 (57%) 73 (60%) .71
Breast cancer 
phenotype
HR+/HER2- 129 (45%) 74 (45%) 55 (45%) .60
HR-/HER2- 82 (29%) 46 (28%) 36 (30%)
HR+/HER2+ 38 (13%) 23 (14%) 18 (15%)
HR-/HER2+ 35 (12%) 23 (14%) 12 (10%)
Radiation 196 (73%) 118 (74%) 78 (72%) .72
Chemotherapy timing
Neoadjuvant 110 (39%) 75 (46%) 35 (29%) .007




AC-T 90 (32%) 59 (36%) 31 (25%) <.001
AC-TC plus anti-
HER2 therapy
22 (8%) 18 (11%) 4 (3%)
TC ± anti-HER2 
therapy
74 (26%) 40 (25%) 34 (28%)
TCH 47 (17%) 33 (20%) 14 (12%)
Other 59 (19%) 18 (10%) 41 (31%)
Duration of chemo-
therapy >3 mo





156 (55%) 80 (49%) 76 (63%) .021
Anthracycline-based 128 (45%) 83 (51%) 45 (37%)
Hospitalization
Yes 47 (17%) 31 (19%) 17 (12%) .19
No 236 (83%) 131 (81%) 103 (73%)
Dose reduction
Yes 93 (33%) 56 (34%) 37 (31%) .50
No 191 (67%) 107 (66%) 84 (69%)
Dose delay
Yes 66 (23%) 36 (22%) 30 (25%) .59
No 218 (77%) 127 (78%) 91 (75%)
Early treatment 
discontinuation
Yes 45 (16%) 26 (16%) 19 (16%) .95
No 239 (84%) 137 (84%) 102 (84%)
Abbreviations: -, negative; +, positive; AC-T, dose-dense doxorubicin and cyclophosphamide followed by paclitaxel; AC-TC, doxorubicin and cyclophosphamide 
plus paclitaxel and carboplatin; HR, hormone receptor; TC, docetaxel and cyclophosphamide; TCH, docetaxel and carboplatin with anti-HER2 therapy.
aBold type indicates statistical significance.
TABLE 2. Patient-Reported Symptom Severity (MSVS) of Anthracycline-Based and Nonanthracycline 
Chemotherapy Regimens in Younger Versus Older Patients (Shown as the Percentage)
Symptom
Anthracycline-Based 
(AC-T and AC-TC) Pa
Nonanthracycline-Based 
(TC and TCH) Pa
Mean total no. of symptoms rated MSVS
Age <65 y 6.9 ± 4.0 .21 5.4 ± 4.1 .25
Age ≥65 y 6.0 ± 3.5 6.2 ± 3.7
Fatigue, lack of energy
Age <65 y 63 (77%) .34 49 (61%) .16
Age ≥65 y 37 (84%) 54 (72%)
Anxiety
Age <65 y 38 (46%) .49 32 (40%) .61
Age ≥65 y 23 (51%) 33 (44%)
Depression
Age <65 y 28 (34%) .54 21 (26%) .81
Age ≥65 y 13 (29%) 21 (28%)
Insomnia
Age <65 y 55 (67%) .13 48 (60%) .87
Age ≥65 y 24 (53%) 46 (61%)
Hot flashes
Age <65 y 40 (49%) <.001 30 (38%) .009
Age ≥65 y 8 (18%) 14 (19%)
Dyspnea
Age <65 y 18 (22%) .38 14 (18%) .17
Age ≥65 y 13 (29%) 20 (27%)
Aching joints/arthralgia
Age <65 y 40 (49%) .15 22 (28%) .005
Age ≥65 y 16 (36%) 37 (49%)
Aching muscles/myalgia
Age <65 y 39 (48%) .19 25 (31%) .33
Age ≥65 y 16 (36%) 29 (39%)
Peripheral neuropathy
Age <65 y 35 (43%) .36 17 (21%) .06
Age ≥65 y 23 (51%) 26 (35%)
Edema limbs
Age <65 y 20 (24%) .99 18 (23%) .33
Age ≥65 y 11 (24%) 22 (29%)
Abdominal pain
Age <65 y 16 (20%) .38 16 (20%) .33
Age ≥65 y 6 (13%) 20 (27%)
General pain
Age <65 y 39 (48%) .07 31 (39%) .87
Age ≥65 y 14 (31%) 30 (40%)
Constipation
Age <65 y 39 (48%) .92 20 (25%) .19
Age ≥65 y 21 (47%) 26 (35%)
Diarrhea
Age <65 y 26 (32%) .49 44 (55%) .97
Age ≥65 y 17 (38%) 41 (55%)
Nausea
Age <65 y 40 (49%) .23 23 (29%) .43
Age ≥65 y 17 (38%) 26 (35%)
Vomiting
Age <65 y 7 (9%) .64 10 (13%) .22
Age ≥65 y 5 (11%) 5 (7%)
Mucositis oral
Age <65 y 26 (32%) .74 15 (19%) .99
Age ≥65 y 13 (29%) 14 (19%)
Hospitalization
Age <65 y 19 (23%) .90 12 (15%) .17
Age ≥65 y 10 (22%) 7 (9%)
Dose reduction
Age <65 y 35 (42%) .08 21 (26%) .36
Age ≥65 y 12 (27%) 25 (33%)
Dose delay
Age <65 y 28 (34%) .41 8 (10%) .02
Age ≥65 y 12 (27%) 18 (24%)
interference associated with hot flashes (26% vs 9%; 
P = .006), whereas a higher percentage of older women 
reported MSVS interference associated with abdominal 
pain (13% vs 28%; P = .02). For all other symptoms 
within the 2 regimen groups, there were no statistically 
significant differences noted between younger and older 
women.
Adverse Events During Chemotherapy
For all chemotherapy regimens combined (Table 1), there 
were no significant differences observed between older 
and younger patients with regard to hospitalization (19% 
vs 12%; P = .19), dose reduction (34% vs 31%; P = .50), 
dose delay (22% vs 25%; P = .59), or early treatment 
discontinuation (16% vs 16%; P = .95). However, 
among women who received a non–anthracycline-
based regimen, younger women experienced fewer dose 
delays compared with older women (10% vs 24%; P 
= .02) Among all participants combined, the primary 
reasons for dose reductions were peripheral neuropathy 
(34%), neutropenic fever (13%), anemia (5%), and 
miscellaneous other (48%); the primary reasons for early 
treatment discontinuation were peripheral neuropathy 
(28%) and miscellaneous other (72%); and the primary 
reasons for hospitalization were neutropenic fever (28%) 
and miscellaneous other (72%).
DISCUSSION
Over the past decade, there has been growing evidence 
from treatment trials that women aged ≥65 years can 
be fit and otherwise well suited for a wide variety of 
chemotherapy regimens. Rather than using age as the sole 
determinant of chemotherapy use, there is strong evidence 
that a brief assessment of function, cognition, and social 
circumstances can provide essential information regarding 
suitability for chemotherapy in the older patient.9,10,25
In the current study, we reported that patient-re-
ported symptom severity and symptom interference with 
daily activities were found to demonstrate little difference 
between older and younger patients for 17 symptoms as-
sociated with chemotherapy regimens commonly used in 
current clinical practice. Older and younger patients re-
ported similar symptom severity regardless of whether the 
regimen was anthracycline-based or not. One exception 
was the side effect of hot flashes, which should have been 
expected to be a greater concern in younger women, espe-
cially those who were premenopausal or perimenopausal 
at the time of breast cancer diagnosis. The data from the 
current study support findings from other studies com-
paring older and younger women who were receiving 
treatment for breast cancer who similarly reported few 
significant differences with regard to symptom severity,26 
with the exception of dyspnea (which was found to be less 
severe in older patients)29 and greater sleep impairment 
in patients aged ≥50 years,28 although it should be noted 
that the chemotherapy regimens in these prior studies dif-
fered from the regimens used in the current study.
A strength of the current study was the collec-
tion of prospective data regarding 327 women who 
were receiving chemotherapy, approximately 43% of 
whom were aged ≥65 years. We reported symptom 
severity as well as interference with activities of daily 
living. However, as we noted in our previous work,17 
a limitation of the current study was that we collected 
patient-reported symptoms according to cycle length 
(every 2 or 3 weeks) within the time frame of “the past 7 
days.” As a consequence, brief symptom spikes that had 
abated from one week to the next may not have been 
apparent. We were unable to speculate as to whether 
this might have systematically biased our study results, 
but are unaware of data suggesting that the duration of 
symptom intensity within a 2-week to 3-week cycle can 
vary by age. We collected, on average, a similar num-
ber of total symptom reports in both age groups (see 
Supporting Table 1).
Separately, and more important, participants in 
the current study were deemed by their treating clini-
cian to be appropriate candidates for chemotherapy, and 
Symptom
Anthracycline-Based 
(AC-T and AC-TC) Pa
Nonanthracycline-Based 
(TC and TCH) Pa
Early treatment discontinuation
Age <65 y 17 (20%) .71 9 (11%) .55
Age ≥65 y 8 (18%) 11 (14%)
Abbreviations: AC-T, dose-dense doxorubicin and cyclophosphamide followed by paclitaxel; AC-TC, doxorubicin and cyclophosphamide plus paclitaxel and car-
boplatin; MSVS, moderate, severe, or very severe; TC, docetaxel and cyclophosphamide; TCH, docetaxel and carboplatin with anti-HER2 therapy.
P values for categorical variables were based on the chi-square test for comparing percentages across age groups; P values for continuous variables were based 
on the 2-sample Student t test for comparing means across age groups.
aBold type indicates statistical significance.
TABLE 2. Continued
provider bias regarding whether to offer chemotherapy 
to older patients or to offer specific regimens could not 
be addressed. Thus, the current study findings in older 
women may represent the experience of a particularly fit 
subgroup of patients who were deemed appropriate for 
chemotherapy.
Figure 1. Anthracycline-based chemotherapy. Patient-reported moderate, severe, or very severe symptom severity and interference 
with daily activities (shown as percentage) for each symptom for younger (aged <65 years) versus older (aged ≥65 years) patients.
Asterisks represent significant differences.
Finally, we noted that all study participants were 
enrolled in a self-directed walking program. Very few pa-
tients who were identified by the research team as potential 
study participants were deemed inappropriate for a mod-
erate exercise study by their treating oncologist. In general, 
both older and younger patients who were deemed “fit” for 
Figure 2. Non–anthracycline-based chemotherapy. Patient-reported moderate, severe, or very severe symptom severity and 
interference with daily activities (shown as percentage) for each symptom for younger (aged <65 years) versus older (aged ≥65
years) patients. Asterisks represent significant differences.
chemotherapy were fit for self-directed walking. Symptom 
experience may have been moderated in women who en-
gaged in walking during chemotherapy compared with those 
who did not engage in walking. We previously reported that 
engaging in moderate walking during chemotherapy is very 
challenging, even among women aged <65 years who were 
enrolled in our intervention studies.29
Although the women in the current study scored 
symptom interference as consistently lower than symp-
tom severity, the high prevalence of moderate or higher 
TABLE 3. Patient-Reported Symptom Interference With Daily Activities (MSVS) of Anthracycline-Based and 
Nonanthracycline Chemotherapy Regimens in Younger Versus Older Patients (Shown as the Percentage)
Symptom
Anthracycline-Based (AC-T and 
AC-TC) Pa Nonanthracycline (TC and TCH) Pa
Fatigue, lack of energy
Age <65 y 59 (72%) .32 43 (54%) .10
Age ≥65 y 36 (80%) 50 (67%)
Anxiety
Age <65 y 21 (26%) .90 17 (21%) .68
Age ≥65 y 12 (27%) 18 (24%)
Depression
Age <65 y 15 (18%) .94 14 (18%) .80
Age ≥65 y 8 (18%) 12 (16%)
Insomnia
Age <65 y 42 (51%) .15 30 (38%) .63
Age ≥65 y 17 (38%) 31 (41%)
Hot flashes
Age <65 y 26 (32%) .001 21 (26%) .006
Age ≥65 y 3 (7%) 7 (9%)
Dyspnea
Age <65 y 16 (20%) .72 16 (20%) .55
Age ≥65 y 10 (22%) 18 (24%)
Aching joints/arthralgia
Age <65 y 30 (37%) .38 21 (26%) .54
Age ≥65 y 13 (29%) 23 (31%)
Aching muscles/myalgia
Age <65 y 31 (38%) .02 21 (26%) .60
Age ≥65 y 8 (18%) 17 (23%)
Peripheral neuropathy
Age <65 y 22 (27%) .61 12 (15%) .86
Age ≥65 y 14 (31%) 12 (16%)
Edema limbs
Age <65 y 14 (17%) .92 13 (16%) .69
Age ≥65 y 8 (18%) 14 (19%)
Abdominal pain
Age <65 y 9 (11%) .71 10 (13%) .02
Age ≥65 y 4 (9%) 21 (28%)
General pain
Age <65 y 33 (40%) .20 22 (28%) .80
Age ≥65 y 13 (27%) 22 (29%)
Constipation
Age <65 y 22 (27%) .08 14 (18%) .83
Age ≥65 y 6 (13%) 12 (16%)
Diarrhea
Age <65 y 19 (23%) .90 33 (41%) .99
Age ≥65 y 10 (22%) 31 (41%)
Nausea
Age <65 y 37 (45%) .12 22 (28%) .80
Age ≥65 y 14 (31%) 22 (29%)
Vomiting
Age <65 y 7 (9%) .64 12 (15%) .40
Age ≥65 y 5 (11%) 8 (11%)
Mucositis oral
Age <65 y 16 (20%) .58 8 (10%) .89
Age ≥65 y 7 (16%) 7 (9%)
Abbreviations: AC-T, dose-dense doxorubicin and cyclophosphamide followed by paclitaxel; AC-TC, doxorubicin and cyclophosphamide plus paclitaxel and car-
boplatin; MSVS, moderate, severe, or very severe; TC, docetaxel and cyclophosphamide; TCH, docetaxel and carboplatin with anti-HER2 therapy.
P values for categorical variables were based on the chi-square test for comparing percentages across age groups; P values for continuous variables were based 
on the 2-sample Student t test for comparing means across age groups.
aBold type indicates statistical significance.
symptom severity in both age groups underscores the im-
portance of ongoing symptom monitoring in patients of all 
ages and communication regarding symptom management 
with the treatment team.30,31 It is perhaps easier for pa-
tients to communicate that a symptom is interfering with 
their daily activities rather than convey the absolute sever-
ity of a symptom, which may explain why clinicians are re-
ported to often underestimate actual symptom intensity.18
Conclusions
Women aged <65 years and those aged ≥65 years who 
are undergoing chemotherapy for early breast cancer have 
reported similarly high levels of MSVS treatment-related 
symptoms. Overall, both older and younger women ap-
peared to perceive symptom interference with activities of 
daily living as being less concerning than symptom severity. 
The findings of the current study confirm those of prior 
studies demonstrating that chemotherapy options need not 
be constrained by the chronological age of the patient.
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